Disc Medicine's stock fell 22% after the FDA issued a Complete Response Letter rejecting its new drug application for bitopertin due to insufficient evidence. The Rosen Law Firm is investigating potential securities claims and preparing a class action lawsuit on behalf of shareholders who may have been misled by the company's business information. Investors who purchased Disc Medicine securities might be eligible for compensation through a contingency fee arrangement. Those interested can join the class action by contacting the Rosen Law Firm.
Danaher Corporation reported stronger-than-expected Q2 2026 earnings and revenue, driven by its Life Sciences segment, with EPS of $1.94 and revenue of $6.27 billion beating estimates. However, the stock fell nearly 12% in premarket trading due to in...
Hancock Whitney Corporation is set to report its Q2 earnings on July 21, 2026, with analysts expecting an EPS of $1.55 and revenue near $399 million. The bank recently gained regulatory approval to acquire One Florida Bank, a strategic move expected ...
A new report reveals more than 180 companies are actively developing over 200 PD-1 and PD-L1 inhibitors, a class of immunotherapies that boost the immune system to fight cancer. These drugs target various cancers including lung, bladder, liver, and e...
Eversource has been recognized on TIME's list of America's Best Companies for 2026, highlighting its strong commitment to employee satisfaction, operational excellence, and sustainability. The ranking is based on surveys of over 217,000 employees and...
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2036, fueled by rising cancer incidence and the introduction of novel immunotherapies and targeted treatments....
